CPR Invest - MedTech enable investors to benefit from medical technology theme in its widest sense.
Its objective is to outperform global equity markets over a long-term period (minimum of five years) by investing in international equities of companies involved in the medical technology ecosystem, while integrating Environmental, Social and Governance (ESG) criteria in the investment process.
A central role in the evolution of healthcare & services
Faced with a growing population, also increasingly ageing, the health sector must adapt to the large number of patients and to their new needs.
Medical technologies (MedTech) can provide assistance at all levels, from prevention to cure, diagnosis, treatment of diseases, surgical interventions and medical follow-up.
They can improve services and care based on constant innovation: computer-assisted surgery, connected hearing aids, etc. They can also cut medical costs by, for example, reducing hospitalization time through less invasive surgery, or by shifting care to the patients home: a person with diabetes can, for example, carry out routine check-ups alone at home - or elsewhere - using an application set up by his or her doctor
A large and diversified universe
Even with a common goal, the companies involved in medical technology are diverse and varied. Some are developing heavy technologies, such as surgical robots, while others are working on simpler products, such as blood pressure bracelets. They offer single- or multiple-use solutions and everyday tools that are intended for:
Healthcare professionals: imaging tools (scanner, MRI, etc.), automated machines (laser operation, etc.), softwares to better process patient files, etc.
Patients: prostheses, mobile applications, disposable lenses, implants, etc.
ACTIVE AND CONVICTION-BASED MANAGEMENT
The fund’s objective is to outperform global equity markets over a long-term period (minimum of 5 years) by investing in international equities of companies involved in the medical technology ecosystem, while integrating Environmental, Social and Governance (ESG) criteria in the investment process.
To do so, the management team has split the investment universe into nine categories: noninvasive devices (glasses, hearing aids, etc.), surgery, blood/dialysis, imaging/radiotherapy, cardiology/neurology, medical supplies, diagnosis tools, orthopedics and IT tools and services (softwares, laboratories, etc.). Within these categories, the eligible investment universe is defined by combining:
A sustainable approach to exclude the companies with a bad ESG rating (on a global scale or on specific criteria linked to the investment theme) and/or subjected to ESG controversies.
A fundamental analysis to identify the seemingly most-promising companies on financial criteria or according to their mid-long term outlook.
The about 60 stocks in the final portfolio will be selected on this basis and according to the conviction level of the management team on these stocks.
Points of attention
Risk of capital loss
No performance guarantee
Recommended investment period: more than 5 years
The variance in the share price may have a negative impact on the sub-fund's net asset value
A decrease in the exchange rate may result in a loss in the sub-fund's net asset value
Due to its composition and strategy, the sub-fund may experience high volatility, which may lead to upward or downward fluctuations in the net asset value over short periods
The theme distinguishes itself by its sector choices; when the financial markets are driven by sectors not included in the theme, the sub-fund may not benefit from all the market growth
